Overview of FINEARTS-HF Trial

Javed Butler, MD, MPH, MBA, discusses the FINEARTS-HF trial presented at European Society of Cardiology Congress 2024, highlighting its objective to evaluate finerenone in patients with heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF, the randomized design, and results indicating a reduction in worsening HF events compared with placebo.

Now Viewing

EP: 1.Overview of FINEARTS-HF Trial

EP: 2.Role of MRAs in HFmrEF and HFpEF

EP: 3.Overview of BB Use and Outcomes in HFmrEF and HFpEF

EP: 4.Multi-Modal Treatment Strategy for HFmrEF and HFpEF

EP: 5.Unmet Needs in the HFmrEF and HFpEF Landscape

EP: 6.Overview of DAPA ECHO Trial

Video content above is prompted by the following:

1. Discuss the data presented at European Society of Cardiology Congress 2024 on the FINEARTS-HF trial evaluating finerenone use among patients with heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF.
2. What was the objective of this study?
3. How was this study designed, and what methodology was used?
4. What results were presented?

Related Videos